Rett Syndrome Behaviour Questionnaire (RSBQ) Total Score - Change From Baseline to Week 12
| Group | Value (score on a scale) | Spread |
|---|---|---|
| Drug - Trofinetide | -4.9 | 0.94 |
| Placebo | -1.7 | 0.90 |
Trial · Interventional
CompletedPhase 3Results postedRegistry dataUnited States
1 trial · 1 completed · 1 with posted results
Study of Trofinetide for the Treatment of Girls and Women With Rett Syndrome (LAVENDER™)
NCT041817236 Nov 2019 to 28 Oct 2021
Text and fields below are the sponsor's entries at ClinicalTrials.gov, shown as posted.
To investigate the efficacy of treatment with oral trofinetide versus placebo in females with Rett syndrome
Experimental
Drug - Trofinetide
Trofinetide solution of 30-60 mL based on the subject's weight at Baseline, administered twice daily by mouth or gastrostomy tube (G-tube)
Placebo comparator
Placebo
Trofinetide placebo solution of 30-60 mL based on the subject's weight at Baseline, administered twice daily by mouth or gastrostomy tube (G-tube)
Outcomes the sponsor listed as primary.
Rett Syndrome Behaviour Questionnaire (RSBQ) Total Score - Change From Baseline to Week 12
Time frame · Baseline and Week 12
The RSBQ is a 45-item caregiver-completed rating scale that includes 45 items, 39 of them grouped into 8 subscales, whose ratings reflect the severity and frequency of symptoms. Items are rated as 0 (not true), 1 (somewhat or sometimes true), or 2 (very true). The 8 subscales are general mood, breathing problems, hand behavior, face movements, body rocking/expressionless face, night-time behaviors, fear/anxiety, and walking/standing. Scores for item 31 are reversed in the calculation of the total score. The total score ranges from 0 to 90 and is calculated as the sum of the item scores. Higher scores mean worse behaviour.
Clinical Global Impression-Improvement (CGI-I) Score at Week 12
Time frame · 12 Weeks Treatment Duration
To rate how much the subject's illness has improved or worsened relative to a baseline state, a 7-point scale is used from 1=very much improved, 2=much improved, 3=minimally improved, 4=no change, 5=minimally worse, 6=much worse, 7=very much worse.
Change From Baseline to Week 12 in Communication and Symbolic Behavior Scales Developmental Profile™ Infant-Toddler Checklist - Social Composite Score (CSBS-DP-IT Social)
Time frame · 12 Weeks Treatment Duration
Standardized screening scale for assessing communication and pre-linguistic skills in young children 12-24 months and can be used with older children with developmental delay. The CSBS-DP includes a suite of three separate measures: The Infant-Toddler Checklist, a follow-up Caregiver Questionnaire and a Behavior Sample. In this study only the Infant-Toddler (CSBS-DP-IT) Checklist was used. The CSBS-DP-IT Checklist is a 24-item rating scale and each item is scored using a three-level rating of frequency: "not yet", "sometimes" and "often". The CSBS-DP-IT Social Composite score the range was 0 to 26 and a higher score represented a worse outcome. Three composite scores can be calculated: 1) Social Composite; 2) Speech Composite; 3) Symbolic Composite.
Change From Baseline to Week 12 in Impact of Childhood Neurologic Disability Scale (ICND) Total Score
Time frame · 12 Weeks Treatment Duration
The Impact of Childhood Neurologic Disability (ICND) scale evaluates the effect of four conditions or health problems on 11 aspects of a child's or family's life as "A lot", "Some", "A little", "Not at all", or "Does not apply". The four conditions or health problems are 1) inattentiveness, impulsivity, or mood, 2) ability to think and remember, 3) neurologic or physical limitations, and 4) epilepsy. The ICND score the range of 0 to 132 and a higher score represents a worse outcome.
Change From Baseline to Week 12 in Rett Syndrome Clinician Rating of Hand Function (RTT-HF)
Time frame · 12 Weeks Treatment Duration
Clinical assessment of the subject's ability to use their hands for functional purposes (such as reaching for and grasping objects, self-feeding, or drawing). The assessment is made on an 8-point Likert scale (0-7) with 0 denoting normal functioning and 7 the most severe impairment.
Change From Baseline to Week 12 in Rett Syndrome Clinician Rating of Ambulation and Gross Motor Skills (RTT-AMB)
Time frame · 12 Weeks Treatment Duration
Clinical assessment of the subject's ability to sit, stand, and ambulate (e.g., walking, running, and climbing stairs). The assessment was made on an 8-point Likert scale (0 to 7), with 0 denoting normal functioning and 7 as the most severe impairment.
Change From Baseline to Week 12 in Rett Syndrome Clinician Rating of Ability to Communicate Choices (RTT-COMC)
Time frame · 12 Weeks Treatment Duration
Clinical assessment of the subject's ability to communicate their choices or preferences, which can include the use of nonverbal means such as eye contact or gestures. The assessment is made on an 8-point Likert scale (0-7) with 0 denoting normal functioning and 7 the most severe impairment.
Change From Baseline to Week 12 in Rett Syndrome Clinician Rating of Verbal Communication (RTT-VCOM)
Time frame · 12 Weeks Treatment Duration
Clinical assessment of the subject's ability to communicate verbally (e.g. words and phrases). The assessment is made on an 8-point Likert scale (0-7) with 0 denoting normal functioning and 7 the most severe impairment.
Change From Baseline to Week 12 in Clinical Global Impression-Severity (CGI-S)
Time frame · 12 Weeks Treatment Duration
A 7 point scale that rates the severity of the subject's illness at the time of assessment, relative to the clinician's experience with subjects who have the same diagnosis. A subject is assessed on severity of illness at the time of rating: 1, normal, not at all ill; 2, borderline ill; 3, mildly ill; 4, moderately ill; 5, markedly ill; 6, severely ill; or 7, extremely ill.
Change From Baseline to Week 12 in Rett Syndrome Caregiver Burden Inventory (RTT-CBI) Total Score (Items 1-24)
Time frame · 12 Weeks Treatment Duration
The Rett Syndrome Caregiver Burden Inventory (RTT-CBI) scale is intended to directly address caregiver burden and indirectly assess the significance of treatment effects on function in the context of activities of daily living. Ratings are on a 5-point Likert scale including: 0-never; 1-rarely; 2-sometimes; 3-frequently and 4-nearly always. As in the original Caregiver Burden Inventory, the RTT-CBI has 24 negatively worded items (items 1 through 24) yielding a total score up to 96. The RTT-CBI the range is 0 to 96 and a higher score represents a worse outcome.
Change From Baseline to Week 12 in Overall Quality of Life Rating of the Impact of Childhood Neurologic Disability Scale (ICND)
Time frame · 12 Weeks Treatment Duration
The overall quality of life of the subject is also rated by responding to the following: "Please rate your child's overall 'Quality of Life' on the scale below. Choose the number which you feel is best and circle it." The choices range from 1 ("Poor") to 6 ("Excellent").
Values are shown as posted at ClinicalTrials.gov, with their units. PepBank has not converted, pooled or compared them.
| Group | Value (score on a scale) | Spread |
|---|---|---|
| Drug - Trofinetide | -4.9 | 0.94 |
| Placebo | -1.7 | 0.90 |
| Group | Value (score on a scale) | Spread |
|---|---|---|
| Drug - Trofinetide | 3.5 | 0.07 |
| Placebo | 3.8 | 0.07 |
| Group | Value (score on a scale) | Spread |
|---|---|---|
| Drug - Trofinetide | -0.1 | 0.26 |
| Placebo | -1.1 | 0.25 |
| Group | Value (score on a scale) | Spread |
|---|---|---|
| Drug - Trofinetide | -6.5 | 3.44 |
| Placebo | -1.9 | 3.14 |
| Group | Value (score on a scale) | Spread |
|---|---|---|
| Drug - Trofinetide | -0.1 | 0.08 |
| Placebo | 0.0 | 0.07 |
| Group | Value (score on a scale) | Spread |
|---|---|---|
| Drug - Trofinetide | -0.2 | 0.07 |
| Placebo | 0.0 | 0.07 |
| Group | Value (score on a scale) | Spread |
|---|---|---|
| Drug - Trofinetide | -0.4 | 0.11 |
| Placebo | 0.0 | 0.10 |
| Group | Value (score on a scale) | Spread |
|---|---|---|
| Drug - Trofinetide | 0.0 | 0.06 |
| Placebo | 0.0 | 0.06 |
| Group | Deaths | Serious events | Other events |
|---|---|---|---|
| Drug - TrofinetideTrofinetide solution of 30-60 mL based on the subject's weight at Baseline, administered twice daily by mouth or gastrostomy tube (G-tube) Trofinetide: Trofinetide solution administered based on the subject's weight at Baseline, twice daily for 12 weeks | 0 / 93 | 3 / 93 | 81 / 93 |
| PlaceboTrofinetide placebo solution of 30-60 mL based on the subject's weight at Baseline, administered twice daily by mouth or gastrostomy tube (G-tube) Placebo: Trofinetide placebo solution administered based on the subject's weight at Baseline, twice daily for 12 weeks | 0 / 94 | 3 / 94 | 32 / 94 |
Each cell reads participants affected / participants at risk, as the registry posted them.
Registry data comes from ClinicalTrials.gov. Study results come from studies, not from the registry. How PepBank works
Studies that cite this trial.
2 studies on this page
Indexing hint: Clinical trial · 2024
Darwish et al. 2024Advances in therapycited by 3
PMID 38363467PMC10960884DOI 10.1007/s12325-024-02796-yPUB-38363467
Indexing hint: Randomized controlled trial · 2023
Neul et al. 2023Nature medicinecited by 154
PMID 37291210PMC10287558DOI 10.1038/s41591-023-02398-1PUB-37291210
1 study on this page
Indexing hint: Clinical trial · 2022
Neul et al. 2022Contemporary clinical trialscited by 54
PMID 35149233DOI 10.1016/j.cct.2022.106704PUB-35149233
References listed at the registry that are not in PepBank. They link to PubMed.
Who could join, as posted.
PepBank is a research reference. Talk to a doctor before you use any peptide.
In PepBank now:147 peptides, 6 blends and 13 other compounds97,577 study results from 17,383 studies8,473 clinical trialsUpdated